The Journal of Vascular and Interventional Radiology doled out its 2017 JVIR Editor's Best awards at this week's Society of Interventional Radiology (SIR) annual meeting in Los Angeles.
The award for Outstanding Clinical Study was given to Dr. Etay Ziv, PhD, from Memorial Sloan Kettering Cancer Center for his paper, "Gene signature associated with upregulation of the Wnt/b-Catenin signaling pathway predicts tumor response to transarterial embolization."
JVIR Editor-in-Chief Dr. Ziv Haskal said the research identified gene mutations and variable sensitivities in tumors treated by interventional radiology with transarterial embolization.
"It may lead to precision patient care by integrating a patient's genetic marker information into oncologic decision-making," Haskal said in a SIR statement. "This type of research is scarce, but it points to a future wherein such markers may prove essential for refining outcomes of [interventional radiology] cancer care."
Meanwhile, the award for Outstanding Laboratory Investigation was presented to Dr. Hideyuki Nishiofuku from Nara Medical University in Japan for his paper, "Intra-arterial therapy using micellar nanoparticles incorporating SN-38 in a rabbit liver tumor model."
SN-38 is the active metabolizing agent of the colon cancer drug irinotecan. The research describes the ability to create, load, and deliver nanoparticles that contain SN-38 to rabbit tumors through their hepatic arteries, according to Haskal.
"This research advances a new potential means of targeted chemotherapy delivery for a disease that takes the lives of 50,000 every year in the U.S. alone," he said.
The awards are supported by the SIR Foundation.
